摘要目的 探讨雄激素受体(androgen receptor,AR)在浸润性乳腺癌中的表达情况,及其与乳腺癌分子分型的相关性.方法 收集2016年8-12月浸润性乳腺癌标本870例,采用免疫组织化学方法检测AR、雌激素受体(ER)、孕激素受体(PR)、HER2、Ki-67、GATA3、GCDFP15、乳腺球蛋白、CK5/6、CK14的表达情况,分析AR与乳腺癌组织学类型、分子分型及相关标志物的关系.结果AR在Luminal A型、Luminal B型、HER2过表达型及三阴性乳腺癌中的阳性率分别为96.3%(207/215)、89.8%(378/421)、82.4%(75/91)和37.1%(53/143),四组间差异具有统计学意义(P<0.01);AR阳性与ER、PR、HER2、GATA3、GCDFP15、乳腺球蛋白的表达呈正相关(均P<0.01),与Ki-67、CK5/6、CK14的表达呈负相关(均P<0.01).结论 AR在浸润性乳腺癌中具有较高的阳性率,且主要与ER阳性乳腺癌相关.在三阴性乳腺癌中AR阳性率为最低,但AR具有成为潜在治疗靶点的临床意义.

abstractsObjective To investigate androgen receptor(AR)expression in invasive breast carcinoma and the correlation with surrogate molecular breast carcinoma subtypes.MethodsImmunohistochemical staining of AR and other biomarkers was performed in a cohort of 870 cases of primary invasive breast carcinomas collected from August to December, 2016.The association of AR expression with different histological and surrogate molecular subtypes was analyzed.Results The positive expression rate of AR in the immunohistochemistry-based surrogate subtypes was 96.3%(207/215) for Luminal A, 89.8%(378/421) for Luminal B, 82.4%(75/91) for HER2 overexpression and 37.1%(53/143) for triple negative breast carcinoma, with significant differences among the four groups (P<0.01).AR correlated positively with the expression of ER(P<0.01), PR(P<0.01), HER2(P=0.007), GATA3(P<0.01), GCDFP15(P<0.01)and mammaglobin(P<0.01), while negatively with the expression of Ki-67(P<0.01), CK5/6(P<0.01)and CK14(P<0.01).Conclusions AR exhibits a high expression in invasive breast carcinoma, which is mainly correlated with ER-positive breast carcinoma.Regardless of the relatively low expression rate, AR is a potential therapeutic target in triple negative breast carcinoma.